Chromosomal microarray analysis may be widely regarded as a first-tier method for both pediatric and prenatal cytogenetic testing, but that hasn't convinced some insurers to reimburse such tests.

The American College of Medical Genetics and Genomics, the Society for Maternal-Fetal Medicine, and the American College of Obstetricians and Gynecologists have all updated their guidelines to recommend CMA in certain situations, making the array-based approach the widely considered standard of care.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.